Human lymphocyte activation assay: An in vitro method for predictive immunotoxicity testing

Journal of Immunotoxicology

Volumn 7, Issue 4, 2010, Pages 357-366

  Collinge, Mark ^a   Cole, Susan H ^a   Schneider, Patricia A ^a   Donovan, Carol B ^a   Kamperschroer, Cris ^a   Kawabata, Thomas T ^a  

^a PFIZER INC   (United States)

Author keywords

Cyclosporine; Dexamethasone; Immunosuppression; Influenza; Methotrexate; Mycophenolate; PBMC; Proliferation; Rapamycin

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; DEXAMETHASONE; METHOTREXATE; MYCOPHENOLIC ACID; RAPAMYCIN;

ANALYTIC METHOD; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RODENT; SHEEP ERYTHROCYTE; T CELL DEPENDENT ANTIBODY RESPONSE;

ANTIGENS, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CRYOPRESERVATION; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS; LYMPHOCYTE ACTIVATION; TOXICOLOGY;

OVIS ARIES; RODENTIA;

EID: 78649291201     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.3109/1547691X.2010.523881     Document Type: Article

References (36)

1. Arns, W., Cibrik, D. M., Walker, R. G., Mourad, G., Budde, K., Mueller, E. A. and Vincenti, F. 2006. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 82:1004-1012.
2. Ban, M., Hettich, D. and Cavelier, C. 1995. Use of Mishell-Dutton culture for the detection of the immunosuppressive effect of iron-containing compounds. Toxicol Lett. 81:183-188.
3. Barten, M. J., Dhein, S., Chang, H., Bittner, H. B., Tarnok, A., Rahmel, A., Mohr, F. W. and Gummert, J. F. 2003. Assessment of immunosuppressive drug interactions: Inhibition of lymphocyte function in peripheral human blood. J. Immunol. Methods 283:99-114.
4. Carfi, M., Gennari, A., Malerba, I., Corsini, E., Pallardy, M., Pieters, R., Van Loveren, H., Vohr, H. W., Hartung, T. and Gribaldo, L. 2007. In vitro tests to evaluate immunotoxicity: A preliminary study Toxicology. 229:11-22.
5. Carr, S. F., Papp, E., Wu, J. C. and Natsumeda, Y. 1993. Characterization of human Type I and Type II IMP dehydrogenases. J. Biol. Chem. 268:27286-27290. (Pubitemid 24006448)
6. + lymphocyte activation by cyclosporine A and Rapamune-Sirolimus. Clin Immunol. Immunopathol. 77:221-228.
7. Conley, S. B., al-Uzri, A., So, S. and Salvatierra, O. 1994. Prevention of rejection and graft loss with an aggressive quadruple immunosuppressive therapy regimen in children and adolescents. Transplantation 57:540-544.
8. De Bosscher, K. and Haegeman, G. 2009. Minireview: Latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 23:281-291.
9. de Winter, B. C. and van Gelder, T. 2008. Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrol Dial. Transplant. 23:3386-3388.
10. Dumont, F. I., Staruch, M. I., Koprak, S. L., Melino, M. R. and Sigal, N. H. 1990. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144:251-258.
11. Foster, D. A. and Toschi, A. 2009. Targeting mTOR with rapamycin: One dose does not fit all. Cell Cycle 8:1026-1029.
12. Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K. and Revillard, I. P. 2000. Mechanisms of action of methotrexate. Immunopharmacology 47:247-257.
13. Han, Y. C. and Pruett, S. B. 1995. Mechanisms of ethanol-induced suppression of a primary antibody response in a mouse model for binge drinking. J. Pharmacol. Exp. Ther. 275:950-957.
14. Jensen, S. A. and Dalhoff, K. P. 2001. Cyclosporine therapeutic drug monitoring. Transplant. Proc. 33:3003-3005.
15. Kawabata, T. T. and White, K. L. Jr. 1987. Suppression of the vitro humoral immune response of mouse splenocytes by benzo (a) pyrene metabolites and inhibition of benzo (a) pyrene-induced immunosuppression by alphanaphthoflavone. Cancer Res. 47:2317-2322.
16. Kitchin, I. E., Pomeranz, M. K., Pak, G., Washenik, K. and Shupack, I. L. 1997. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses. J. Am. Acad. Dermatol. 37:445-449.
17. Koeper, L. M. and Vohr, H. W. 2009. Functional assays are mandatory for a correct prediction of immunotoxic properties of compounds in vitro. Food Chem. Toxicol. 47:110-118.
18. Lang, D. S., Meier, K. L. and Luster, M. I. 1993. Comparative effects of immunotoxic chemicals on in vitro proliferative responses of human and rodent lymphocytes. Fundam. Appl. Toxicol. 21:535-545.
19. Lebrec, H., Roger, R., Blot, C., Burleson, G. R., Bohuon, C. and Pallardy, M. 1995. Immunotoxicological investigation using pharmaceutical drugs. In vitro evaluation of immune effects using rodent or human immune cells. Toxicology. 96:147-156.
20. Lee, C. L., Jiang, P. P., Sit, W. H. and Wan, I. M. 2007. Proteome of human T-lymphocytes with treatment of cyclosporine and polysaccharopeptide: Analysis of significant proteins that manipulate T-cells proliferation and immunosuppression. Int. Immunopharmacol. 7:1311-1324.
21. Lindholm, A., Welsh, M., Rutzky, L. and Kahan, B. D. 1993. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. Transplantation 55:985-993.
22. Löwenberg, M., Verhaar, A. P., van den Brink, G. R. and Hommes, D. W. 2007. Glucocorticoid signaling: A nongenomic mechanism for T-cell immunosuppression. Trends Mol Med. 13:158-163.
23. Luster, M. I., Pait, D. G., Portier, C., Rosenthal, G. J., Germolec, D. R., Comment, C. E., Munson, A. E., White, K. and Pollock, P. 1992. Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology. Toxicol Lett. 64-65 Spec No: 71-78.
24. Malago, M., Rogiers, T., Wadström, J., Burdelski, M. and Broelsch, C. E. 1994. Optimal clinical regimens for living related liver transplantation. Transplant. Proc. 26:2665-2668.
25. Malek, T. R. 2008. The biology of interleukin-2. Annu. Rev. Immunol. 26:453-479.
26. Mishell, R. I. and Dutton, R. W. 1966. Immunization of normal mouse spleen cell suspensions in vitro. Science 153:1004-1006.
27. Mishell, R. I. and Dutton, R. W. 1967. Immunization of dissociated spleen cell cultures from normal mice. J. Exp. Med. 126:423-442.
28. Porayko, M. K., Gonwa, T. A., Klintmalm, G. B. and Wiesner, R. H. 1995. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U. S. Multicenter Liver Study Group. Transplant. Proc. 27:1114-1116.
29. Pruett, S. B., Han, Y. C. and Fuchs, B. A. 1992. Morphine suppresses primary humoral immune responses by a predominantly indirect mechanism. J. Pharmacol. Exp. Ther. 262:923-928.
30. Quéméneur, L., Flacher, M., Gerland, L. M., Ffrench, M., Revillard, I. P. and Bonnefoy-Berard, N. 2002. Mycophenolic acid inhibits IL-2-dependent T-cells proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J. Immunol. 169:2747-2755.
31. Shaw, L. M., Figurski, M., Milone, M. C., Trofe, I. and Bloom, R. D. 2007. Therapeutic drug monitoring of mycophenolic acid. Clin. J. Am. Soc. Nephrol. 2:1062-1072.
32. Shaw, L. M., Korecka, M., Venkataramanan, R., Goldberg, L., Bloom, R. and Brayman, K. L. 2003. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am. J. Transplant. 3:534-542.
33. Thomson, A. W., Turnquist, H. R. and Raimondi, G. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:324-337.
34. Waksman, I. C., and Delgado, I. H. 2004. Immunosuppressants. In: Medical Toxicology. 3rd Edition (Dart, R. C., Ed.), New York: Lippincott Williams & Wilkins, pp. 1039-1047.
35. Weijtens, O., Schoemaker, R. C., Cohen, A. F., Romijn, F. P., Lentjes, E. G., van Rooij, I. and van Meurs, I. C. 1998. Dexamethasone concentration in vitreous and serum after oral administration. Am. J. Ophthalmol. 125:673-679.
36. Wood, M. A., and Bierer, B. E. 1994. Rapamycin: Biological and therapeutic effects, binding by immunophilins and molecular targets of action. Perspect. Drug Disc. Design 2:163-184.